FDA-approved for one specific indication
PT-141 (Bremelanotide)
A melanocortin receptor agonist. Bremelanotide (Vyleesi®) is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; other uses are investigational.
Evidence-based care
Individualized plan
Overview and regulatory status
A melanocortin receptor agonist. Bremelanotide (Vyleesi®) is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; other uses are investigational.
Availability, if any, is decided only after an individual evaluation by a licensed provider.
Safety first
Who should not use it
- Severe high blood pressure
- Certain heart conditions or fluid restriction
- Pregnancy or breastfeeding (consult your provider)
- All current medications and supplements are reviewed for interactions
Next step
Talk with a provider first
Every plan starts with a medical evaluation by a licensed provider.
Information on this page is educational and does not replace medical evaluation. Treatment options are determined individually.